Skip to content
Back to AVIR

Atea Pharmaceuticals, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
1
Purchases
1
Sales
0
Purchase value
$25.45K
Sale value
$0.00

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Polly A. MurphyDirector
4/AAmendment
Filed May 21, 2026Period of report May 18, 20260001193125-26-235039
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 18, 2026
Common StockF1F26,100$4.1715$25.45K92,145Direct
Filing footnotes · 2
  1. F1This Form 4/A has been filed solely to correct the date of the transaction reported in Column 2 of Table I of the Reporting Person's Form 4 filed on May 20, 2026, which was inadvertently noted as "May 18, 2025" instead of "May 18, 2026."
  2. F2The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $4.14 to $4.19 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.